Sign inJoin waitlistJoin the waitlist

Farzana Pashankar

Fellowship Director, Pediatric Hematology & Oncology Program · Yale-New Haven Hospital

Credentials: · · ·

History

Pediatric Hematology & Oncology Program Fellowship · Yale-New Haven Hospital
Present
Pediatrics Department · Yale-New Haven Hospital
Present
Yale-New Haven Hospital
Present

British Columbia Children’s Hospital and University of Iowa
2006–2008
British Columbia Children’s Hospital and University of Iowa
2003–2006
University of Iowa Health Care Medical Center
2000–2003
BC Children's Hospital
1996–1999
BYRAMJEE JEEJEEBHOY MED COLL, UNIV OF POONA, POONA, MAHARASHTRA
1988–1992
Sassoon General Hospital
1988–1991
Savitribai Phule Pune University
1986–1989

Research

Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
Case report · Nature Communications · 2020 · 155 citations
Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States
Journal of Clinical Oncology · 2015 · 113 citations
Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series
Case report · Transfusion · 2016 · 108 citations

Lindsay Frazier
24 papers
Carlos Rodriguez-Galindo
19 papers
Deborah Billmire
18 papers
James Amatruda
13 papers
TO
Thomas Olson
9 papers
Marcio Malogolowkin
8 papers
BD
Bryan Dicken
6 papers
JC
Judith Carbonella
6 papers
Alberto Pappo
5 papers
Frederick Rescorla
5 papers
Jonathan Ross
5 papers
David Gershenson
4 papers

Clinical trials

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
Site PI · Recruiting · Phase 2
Children's Oncology Group
2024–2033